Go back

Rivaroxaban Revs Up For European Impact

Bayer’s anticoagulant Xarelto® will be eligible in 2026 for generic formulation. Download your free article now to find out more about the opportunities for this bestseller, which earns $12bn in annual sales globally, and over $3.5bn annually in Europe. Discover how to partner with an established supplier to gain the competitive advantage.

Download Content

Published

26 July 2022

Categories

Pharmaceutical,

Type of Content

Article,

Format

PDF,

Enter details below for your free download

    You have the right to unsubscribe at any time, using the update your preferences link on our site. To find out more about how we use your personal information and your rights, please see our Privacy Notice



    Similar content